As of 2026-09-25, the EV/EBITDA ratio of Syros Pharmaceuticals Inc (SYRS) is 0.18. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SYRS's latest enterprise value is -17.18 mil USD. SYRS's TTM EBITDA according to its financial statements is -95.71 mil USD. Dividing these 2 quantities gives us the above SYRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.6x - 16.7x | 16.1x |
| Forward P/E multiples | 17.7x - 19.8x | 18.8x |
| Fair Price | (18,353.54) - (17,287.47) | (18,024.32) |
| Upside | -15660121.1% - -14750503.2% | -15379209.7% |
| Date | EV/EBITDA |
| 2026-09-23 | 0.18 |
| 2026-09-22 | 0.18 |
| 2026-09-21 | 0.18 |
| 2026-09-18 | 0.18 |
| 2026-09-17 | 0.18 |
| 2026-09-16 | 0.18 |
| 2026-09-15 | 0.18 |
| 2026-09-14 | 0.18 |
| 2026-09-11 | 0.18 |
| 2026-09-10 | 0.18 |
| 2026-09-08 | 0.18 |
| 2026-09-04 | 0.18 |
| 2026-09-03 | 0.18 |
| 2026-09-02 | 0.18 |
| 2026-09-01 | 0.18 |
| 2026-08-31 | 0.18 |
| 2026-08-28 | 0.18 |
| 2026-08-27 | 0.18 |
| 2026-08-26 | 0.18 |
| 2026-08-25 | 0.18 |
| 2026-08-24 | 0.18 |
| 2026-08-21 | 0.18 |
| 2026-08-20 | 0.18 |
| 2026-08-19 | 0.18 |
| 2026-08-18 | 0.18 |
| 2026-08-17 | 0.18 |
| 2026-08-14 | 0.18 |
| 2026-08-13 | 0.18 |
| 2026-08-12 | 0.18 |
| 2026-08-11 | 0.18 |
| 2026-08-10 | 0.18 |
| 2026-08-07 | 0.18 |
| 2026-08-06 | 0.18 |
| 2026-08-05 | 0.18 |
| 2026-08-04 | 0.18 |
| 2026-08-03 | 0.18 |
| 2026-07-30 | 0.18 |
| 2026-07-29 | 0.18 |
| 2026-07-28 | 0.18 |
| 2026-07-24 | 0.18 |
| 2026-07-23 | 0.18 |
| 2026-07-22 | 0.18 |
| 2026-07-21 | 0.18 |
| 2026-07-20 | 0.18 |
| 2026-07-17 | 0.18 |
| 2026-07-16 | 0.18 |
| 2026-07-15 | 0.18 |
| 2026-07-14 | 0.18 |
| 2026-07-13 | 0.18 |
| 2026-07-10 | 0.18 |